- Home
- ASTH vs AKRO Comparison
ASTH vs AKRO Comparison
Compare ASTH & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- AKRO
- Stock Information
- Founded
- ASTH 1994
- AKRO 2017
- Country
- ASTH United States
- AKRO United States
- Employees
- ASTH N/A
- AKRO N/A
- Industry
- ASTH Professional Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- AKRO Health Care
- Exchange
- ASTH Nasdaq
- AKRO Nasdaq
- Market Cap
- ASTH 2.0B
- AKRO 2.0B
- IPO Year
- ASTH N/A
- AKRO 2019
- Fundamental
- Price
- ASTH $37.14
- AKRO $25.60
- Analyst Decision
- ASTH Strong Buy
- AKRO Strong Buy
- Analyst Count
- ASTH 6
- AKRO 8
- Target Price
- ASTH $66.40
- AKRO $46.83
- AVG Volume (30 Days)
- ASTH 384.0K
- AKRO 842.7K
- Earning Date
- ASTH 02-25-2025
- AKRO 02-27-2025
- Dividend Yield
- ASTH N/A
- AKRO N/A
- EPS Growth
- ASTH 34.92
- AKRO N/A
- EPS
- ASTH 1.30
- AKRO N/A
- Revenue
- ASTH $1,722,367,000.00
- AKRO N/A
- Revenue This Year
- ASTH $46.11
- AKRO N/A
- Revenue Next Year
- ASTH $34.25
- AKRO N/A
- P/E Ratio
- ASTH $28.80
- AKRO N/A
- Revenue Growth
- ASTH 29.71
- AKRO N/A
- 52 Week Low
- ASTH $29.08
- AKRO $15.32
- 52 Week High
- ASTH $63.20
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- ASTH 59.31
- AKRO 44.22
- Support Level
- ASTH $30.86
- AKRO $21.34
- Resistance Level
- ASTH $32.86
- AKRO $28.94
- Average True Range (ATR)
- ASTH 1.61
- AKRO 1.35
- MACD
- ASTH 1.02
- AKRO -0.09
- Stochastic Oscillator
- ASTH 95.27
- AKRO 56.05
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.